A plasma protein signature for cerebral amyloid angiopathy
Nicholas Ashton, et al., Banner Health Topic/Product: Disease Area: Sample Type: Abstract Cerebral amyloid angiopathy (CAA) is a cerebrovascular disorder
May 20, 2026
The convergence of disease modifying therapies and high-sensitivity protein detection technologies is transforming neurology. These advancements promise earlier diagnoses, personalized treatment plans, and improved patient outcomes across a spectrum of CNS diseases.
Multiplex analysis of biologically informed content with the highest-sensitivity and broadest dynamic range.
Profile Biomarkers of CNS Disease at the Lowest Limit of Detection
The ONLY neurology panel with Brain-Derived Tau assays. Simultaneous analysis of 120 proteins from a single 25ul sample with fg/ml sensitivity empowers researchers to detect disease earlier and differentiate between clinically similar phenotypes.
Discover More Biology in preclinical models
With the largest multiplexed protein panel for mouse studies, researchers can comprehensively measure inflammation from precious small volume samples and maximize the information captured in basic research and preclinical studies.
Ultra-high sensitivity measurement of your most informative biomarkers.
Detect important low abundance proteins with attomolar sensitivity (low fg/mL)
In neurodegenerative conditions marked by Tau accumulation, protein sources may originate from either brain or peripheral tissues. For Alzheimer’s disease, when detecting pTau217 from blood or plasma it is critical to distinctly detect brain originated pTau217 versus that originated from peripheral tissues.
Elevated levels of Neurofilament light (NfL) can indicate the extent of neuronal injury and are useful for diagnosing and monitoring the progression of neurological diseases, such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD), Multiple Sclerosis (MS), etc.
Coming Soon! Overproduction of Interleukin-1 beta (IL-1β) is associated with various inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and certain neurodegenerative disorders like Alzheimer's disease.
Check out these selected publications demonstrating the superior performance of NULISA assays to detect critical cytokines and immune related biomarkers.
Nicholas Ashton, et al., Banner Health Topic/Product: Disease Area: Sample Type: Abstract Cerebral amyloid angiopathy (CAA) is a cerebrovascular disorder
Zhi Yu, et al., Mass General Hospital Topic/Product: Disease Area: Sample Type: Abstract High-throughput affinity-based proteomics has advanced biomedical research,
Topic/Product: Disease Area: Sample Type: Abstract Abstract Background Postoperative delirium is a common complication in older adults and is associated
Carlos Cruchaga, et al., Washington University in St Louis Topic/Product: Disease Area: Sample Type: Abstract INTRODUCTION Accurate clinical diagnosis of
Nicholas Ashton, et al., Banner Health Topic/Product: Disease Area: Sample Type: Abstract Cerebral amyloid angiopathy (CAA) is a cerebrovascular disorder characterized by the deposition of
Zhi Yu, et al., Mass General Hospital Topic/Product: Disease Area: Sample Type: Abstract High-throughput affinity-based proteomics has advanced biomedical research, yet fundamental, persistent discordance between
Topic/Product: Disease Area: Sample Type: Abstract Abstract Background Postoperative delirium is a common complication in older adults and is associated with neuroinflammation and cognitive decline.
Carlos Cruchaga, et al., Washington University in St Louis Topic/Product: Disease Area: Sample Type: Abstract INTRODUCTION Accurate clinical diagnosis of neurodegenerative diseases remains challenging, particularly
AVAILABLE ON DEMAND 8:00 am PT / 11:00 am ET / 4:00 pm BST Featuring: Cheryl Wellington, PhD Professor and Vice Chair Research Djavad Mowafaghian
Tuesday, April 08, 2025 | 2pm EDT / 11am PDT Featuring: Laura Ibáñez, PhD Assistant Professor of Psychiatry, Washington University of Medicine Carlos Cruchaga, PhD
Featuring: Maura Malpetti, PhD UK DRI Emerging Leader Race Against Dementia ARUK Fellow Senior Research Associate University of Cambridge Sterling Johnson, PhD Professor of Geriatrics
Featuring: Sterling Johnson, PhD Professor of Geriatrics and Dementia, Department of Geriatrics and Gerontology, University of Wisconsin Alex Forrest-Hay VP of Sales Alamar Biosciences VIEW
Featuring: Nicholas Ashton, PhD Associate Professor of Neurochemistry University of Gothenburg Alex Forrest-Hay VP of Sales Alamar Biosciences VIEW ON DEMAND The advancement in ultra-sensitive
Featuring: Henrik Zetterberg, MD, PhD Professor of Neurochemistry, University of Gothenburg Doug Hinerfeld, PhD Senior Director of Application Support, Alamar Biosciences VIEW ON DEMAND Brain-derived
AVAILABLE ON DEMAND 8:00 am PT / 11:00 am ET / 4:00 pm BST Featuring: Cheryl Wellington, PhD Professor and
Tuesday, April 08, 2025 | 2pm EDT / 11am PDT Featuring: Laura Ibáñez, PhD Assistant Professor of Psychiatry, Washington University
Featuring: Maura Malpetti, PhD UK DRI Emerging Leader Race Against Dementia ARUK Fellow Senior Research Associate University of Cambridge Sterling
Featuring: Sterling Johnson, PhD Professor of Geriatrics and Dementia, Department of Geriatrics and Gerontology, University of Wisconsin Alex Forrest-Hay VP
Featuring: Nicholas Ashton, PhD Associate Professor of Neurochemistry University of Gothenburg Alex Forrest-Hay VP of Sales Alamar Biosciences VIEW ON
Featuring: Henrik Zetterberg, MD, PhD Professor of Neurochemistry, University of Gothenburg Doug Hinerfeld, PhD Senior Director of Application Support, Alamar
Alzheimer’s Disease (AD)
Biomarkers such as amyloid-β, p-tau, and total tau (t-tau) are critical for early detection and monitoring. High-sensitivity techniques enable the detection of these markers in plasma, making routine screening feasible.
Parkinson’s Disease (PD)
α-synuclein aggregates in CSF and blood are being explored as diagnostic and prognostic markers. High-sensitivity assays can distinguish subtle changes associated with early disease stages.
Amyotrophic Lateral Sclerosis (ALS)
NfL and other neurodegeneration-related proteins serve as reliable indicators of motor neuron injury. Their levels in blood and CSF correlate with disease progression and therapeutic response.
Multiple Sclerosis (MS)
NfL and GFAP are emerging as valuable biomarkers for assessing inflammatory and neurodegenerative processes in MS. High-sensitivity detection enhances the precision of these measurements.
Frontotemporal Dementia (FTD)
Genetic and protein biomarkers, including progranulin and tau, provide insights into FTD subtypes. Sensitive assays enable earlier differentiation from other dementias.
Traumatic Brain Injury (TBI)
Acute biomarkers like GFAP and ubiquitin C-terminal hydrolase L1 (UCH-L1) aid in diagnosing and prognosticating TBI severity. High-sensitivity detection ensures rapid and accurate evaluation in clinical settings.
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
CSO
Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.
CFO
Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.